Blog
RSS FeedPosted by Michael Wonder on 04 Nov 2021
A breakthrough treatment for cystic fibrosis needs funding now
3 November 2021 - Let’s just kick this off by addressing the elephant in the room. Trikafta, the breakthrough treatment ...
Posted by Michael Wonder on 26 Oct 2021
Cystic fibrosis medicine added to PHARMAC's options for investment list
27 October 2021 - PHARMAC has announced that Vertex’s triple combination modulator therapy, known in some countries as Trikafta, has ...
Posted by Michael Wonder on 07 Jul 2021
Access to miracle drug Trikafta a 'lifeline' for cystic fibrosis patients with no other hope
7 July 2021 - A handful of cystic fibrosis patients have been thrown a lifeline with a drug company offering ...
Posted by Michael Wonder on 17 May 2021
New Zealanders living with cystic fibrosis wait for 'life changing' drug
16 May 2021 - Edward Lee and Reese Robertson both have cystic fibrosis. ...
Posted by Michael Wonder on 01 Mar 2021
Proposal to fully fund Mercilon 28 for oral contraception
26 February 2021 - PHARMAC is seeking feedback on a proposal to increase the subsidy to fully fund ethinyloestradiol 20 ...
Posted by Michael Wonder on 17 Feb 2021
Supplier of expensive cystic fibrosis medication yet to apply for PHARMAC approval
17 February 2021 - Government drug-buying agency PHARMAC has revealed the supplier of expensive cystic fibrosis medicine Trikafta still hasn’t ...
Posted by Michael Wonder on 03 Feb 2021
Cystic fibrosis survivor calls for life-saving drug Trikafta to be funded as PHARMAC dangles hope
3 February 2021 - Drug buying agency PHARMAC has revealed it is willing to go directly to the Government for ...
Posted by Michael Wonder on 31 Jan 2021
New Zealand Pharmaceutical Schedule - 1 February 2021
1 February 2021 - The February 2021 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 23 Nov 2020
Ethinyloestradiol 20 mcg with desogestrel 150 mcg and 7 inert tablets (Mercilon 28)
23 November 2020 - Ethinyloestradiol 20 mcg with desogestrel 150 mcg and 7 inert tablets (Mercilon 28) will be fully funded ...
Posted by Michael Wonder on 18 Sep 2020
Decision to fund an additional brand of budesonide with eformoterol
18 September 2020 - PHARMAC is pleased to announce a decision to fund an additional brand of budesonide with eformoterol ...
Posted by Michael Wonder on 04 Aug 2020
Trikafta manufacturer to fast track application to have 'miracle' cystic fibrosis drug funded in New Zealand
4 August 2020 - The miracle drug Trikafta is a step closer for New Zealanders living with cystic fibrosis, after ...
Posted by Michael Wonder on 02 Aug 2020
Access for Aotearoa - campaigning for access to modern medications for Kiwis with cystic fibrosis
3 August 2020 - It took eight years for New Zealanders living with CF to access the first of four ...
Posted by Michael Wonder on 30 Jul 2020
Proposal to fund an additional brand of budesonide with eformoterol
30 July 2020 - PHARMAC is seeking feedback on a proposal to fund an additional brand (DuoResp Spiromax) of two ...
Posted by Michael Wonder on 16 Jul 2020
'Life-changing' drug not accessible for New Zealanders living with cystic fibrosis
17 July 2020 - For Chantelle de Kort, her biggest hope for the future is that she will get to ...
Posted by Michael Wonder on 24 Mar 2020
COVID-19: sacubitril with valsartan (Entresto)
25 March 2020 - Sacubitril with valsartan is a medicine used in the management of clinically significant, treatment refractory heart ...